2021 World Conference on Lung Cancer (Posters)-FP09. Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort

FP09. Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort

Back to course

Video Transcription

Video Summary

Dr. Rosario Aljera-Campelo presented the data on patient-reported outcomes from the Sritan extension core phase 1-2 study of Moxeritinib in previously treated patients with EFR-XON20 insertion positive metastatic non-small cell lung cancer. The study included 96 patients, and Moxeritinib showed statistically significant and clinically meaningful improvements in lung cancer symptoms such as dyspnea, cough, and chest pain. Global health status was maintained or improved in most patients, and general health-related quality of life remained stable throughout treatment. Adverse events such as diarrhea, dry skin, rash, and decreased appetite were reported, but did not significantly impact quality of life. Overall, Moxeritinib showed promise in improving patient outcomes in this difficult-to-treat population.

Asset Subtitle

Maria Rosario García Campelo

Meta Tag

Speaker Maria Rosario García Campelo

Topic Novel Therapeutics and Targeted Therapies

Keywords

Dr. Rosario Aljera-Campelo

patient-reported outcomes

Sritan extension core phase 1-2 study

Moxeritinib

metastatic non-small cell lung cancer